Platelet endothelial cell adhesion molecule targeted oxidant-resistant mutant thrombomodulin fusion protein with enhanced potency in vitro and in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 2, 2013, Pages 339-345

  Carnemolla, Ronald ^a   Greineder, Colin F ^a   Chacko, Ann Marie ^b   Patel, Kruti Rajan ^c   Ding, Bi Sen ^d   Zaitsev, Sergei ^a   Esmon, Charles T ^e   Muzykantov, Vladimir R ^a,b  

^a University of Pennsylvania   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; CD31 ANTIGEN; HYBRID PROTEIN; LEUCINE; METHIONINE; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1 ANTIBODY; PROTEIN ANTIBODY; RECOMBINANT THROMBOMODULIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THROMBIN; THROMBOMODULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY STRUCTURE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INTERACTION; CONTROLLED STUDY; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; STRUCTURE ANALYSIS; THROMBOSIS; VASCULITIS;

ANIMALS; ANTIGENS, CD31; BLOOD COAGULATION; CELL LINE; ENDOTHELIAL CELLS; MALE; MICE; MICE, INBRED C57BL; MUTATION; OXIDATIVE STRESS; PARTIAL THROMBOPLASTIN TIME; PROTEIN BINDING; PROTEIN C; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; SUBSTRATE SPECIFICITY; THROMBIN; THROMBOMODULIN;

EID: 84886004620     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205104     Document Type: Article

References (33)

1. Abrams WR, Weinbaum G, Weissbach L., Weissbach H, and Brot N (1981) Enzymatic reduction of oxidized alpha-1-proteinase inhibitor restores biological activity. Proc Natl Acad Sci USA 78:7483-7486.
2. Aird WC (2003) The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101:3765-3777.
3. Carnemolla R, Patel KR, Zaitsev S, Cines D.B., Esmon CT, and Muzykantov VR (2012) Quantitative analysis of thrombomodulin-mediated conversion of protein C to APC: translation from in vitro to in vivo. J Immunol Methods 384:21-24.
4. Carp H, Miller F, Hoidal J.R., and Janoff A (1982) Potential mechanisms of emphysema: alpha-1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad U S A 79:2041-2045.
5. Chacko AM, Nayak M, Greineder C.F., Delisser HM, and Muzykantov VR (2012) Collaborative enhancement of antibody binding to distinct PECAM-1 epitopes modulates endothelial targeting. PLoS One 4:e34958.
6. Charoenphol P, Mocherla S, Bouis D., Namdee K, Pinsky DJ, and Eniola-Adefeso O (2011) Targeting therapeutics to the vascular wall in atherosclerosis - carrier size matters. Atherosclerosis 217:364-370.
7. Cochrane CG, Spragg R, and Revak SD (1983) Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. J Clin Invest 71:754-761.
8. Ding BS, Gottstein C, Grunow A., Kuo A, Ganguly K, Albelda S.M., Cines DB, and Muzykantov VR (2005) Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 106: 4191-4198.
9. Ding BS, Hong N, Murciano J.C., Ganguly K., Gottstein C, Christofidou-Solomidou M, Albelda SM, Fisher A.B., Cines DB, and Muzykantov VR (2008) Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood 111:1999-2006.
10. Ding BS, Hong NK, Christofidou-Solomidou M, Gottstein C., Albelda SM, Cines DB, Fisher AB, and Muzykantov VR (2009) Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation. Am J Respir Crit Care Med 180:247-256.
11. Eiserich JP, Baldus S, Brennan M.L., Ma W., Zhang C, Tousson A, Castro L., Lusis AJ, Nauseef WM, and White CR, et al. (2002) Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 296:2391-2394.
12. Eiserich JP, Hristova M, Cross C.E., Jones AD, Freeman BA, Halliwell B, and van der Vliet A (1998) Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391:393-397.
13. Esmon CT (2005) Do-all receptor takes on coagulation, inflammation. Nat Med 11: 475-477.
14. Glaser CB, Morser J, Clarke J.H., Blasko E., McLean K, Kuhn I, Chang R.J., Lin JH, Vilander L, and Andrews WH, et al. (1992) Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation. J Clin Invest 90: 2565-2573.
15. Harvath L and Aksamit RR (1984) Oxidized N-formylmethionyl-leucyl- phenylalanine: effect on the activation of human monocyte and neutrophil chemotaxis and superoxide production. J Immunol 133:1471-1476.
16. Ikezoe T, Takeuchi A, Isaka M., Arakawa Y, Iwabu N, Kin T., Anabuki K, Sakai M, Taniguchi A, and Togitani K, et al. (2012) Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk Res 36:1398-1402.
17. Johnson D and Travis J (1978) Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor. J Biol Chem 253:7142-7144.
18. Johnson D and Travis J (1979) The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center. J Biol Chem 254:4022-4026.
19. Koren E and Torchilin VP (2011) Drug carriers for vascular drug delivery. IUBMB Life 63:586-595.
20. Kułdo J.M., Ásgeirsdóttir SA, Zwiers PJ, Bellu AR, Rots MG, Schalk JA, Ogawara KI, Trautwein C, Banas B, and Haisma HJ, et al. (2013) Targeted adenovirus mediated inhibition of NF-kB-dependent inflammatory gene expression in endothelial cells in vitro and in vivo. J Control Release 166:57-65.
21. Kumada T, Dittman WA, and Majerus PW (1988) A role for thrombomodulin in the pathogenesis of thrombin-induced thromboembolism in mice. Blood 71:728-733.
22. Lentz SR (2003) Thrombosis of vein grafts: wall tension restrains thrombomodulin expression. Circ Res 92:12-13.
23. Lawrence DA and Loskutoff DJ (1986) Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry 25:6351-6355.
24. Liaw PC, Ferrell G, and Esmon CT (2003) A monoclonal antibody against activated protein C allows rapid detection of activated protein C in plasma and reveals a calcium ion dependent epitope involved in factor Va inactivation. J Thromb Haemost 1:662-670.
25. Molema G (2010) Heterogeneity in endothelial responsiveness to cytokines, molecular causes, and pharmacological consequences. Semin Thromb Hemost 36:246-264.
26. Mosnier LO, Zlokovic BV, and Griffin JH (2007) The cytoprotective protein C pathway. Blood 109:3161-3172.
27. Ng CK, Deshpande SS, Irani K, and Alevriadou BR (2002) Adhesion of flowing monocytes to hypoxia-reoxygenation-exposed endothelial cells: role of Rac1, ROS, and VCAM-1. Am J Physiol Cell Physiol 283:C93-C102.
28. Stief TW, Aab A, and Heimburger N (1988) Oxidative inactivation of purified human alpha-2-antiplasmin, antithrombin III. And C-1 inhibitor. Thromb Res 50:559-573.
29. van Iersel T., Stroissnig H, Giesen P., Wemer J, and Wilhelm-Ogunbiyi K (2011) Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 105:302-312.
30. Ware LB, Fang X, and Matthay MA (2003) Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 285:L514-L521.
31. Weiler H and Isermann BH (2003) Thrombomodulin. J Thromb Haemost 1: 1515-1524.
32. Wood MJ, Becvar LA, Prieto J.H., Melacini G., and Komives EA (2003) NMR structures reveal how oxidation inactivates thrombomodulin. Biochemistry 42:11932-11942.
33. Zaitsev S, Kowalska MA, Neyman M, Carnemolla R., Tliba S, Ding BS, Stonestrom A, Spitzer D., Atkinson JP, and Poncz M, et al. (2012) Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis. Blood 119:4779-4785.